Literature DB >> 3515174

In vitro inhibition of Plasmodium falciparum by pyrazofurin, an inhibitor of pyrimidine biosynthesis de novo.

H V Scott, A M Gero, W J O'Sullivan.   

Abstract

The effect of pyrazofurin, an inhibitor of UMP synthesis, on Plasmodium falciparum growth in vitro has been studied. ID50 values (concentration of compound causing 50% inhibition of [3H]hypoxanthine incorporation) for the FCQ-27, FCI-1 and K-1 (chloroquine-resistant) isolates were 10 +/- 8.7, 6.4 +/- 5.3 and 6.3 +/- 0.5 microM, respectively. Comparative ID50 values for chloroquine were 13.5 +/- 4.2, 22.8 +/- 7.6 and 343 +/- 114 microM, respectively. Over the 48-h intraerythrocytic cycle of tightly synchronized parasites, pyrazofurin both reduced the parasitemia and retarded the maturation of trophozoites and schizonts. Addition of uracil or uridine to the in vitro culture did not decrease the anti-parasitic activity of pyrazofurin. Chloroquine reduced the parasitemia, but did not retard development of the remaining viable parasites. Pyrazofurin (20 microM) caused a 50% inhibition of parasite orotate phosphoribosyltransferase (E.C. 2.4.2.10) and, in the presence of adenosine kinase and ATP, a 73% inhibition of orotidine-5'-phosphate decarboxylase (E.C. 4.1.1.23).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3515174     DOI: 10.1016/0166-6851(86)90045-9

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  10 in total

1.  Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase.

Authors:  Maria Elena Meza-Avina; Lianhu Wei; Yan Liu; Ewa Poduch; Angelica M Bello; Ram K Mishra; Emil F Pai; Lakshmi P Kotra
Journal:  Bioorg Med Chem       Date:  2010-04-09       Impact factor: 3.641

2.  Pyrophosphate interactions at the transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Authors:  Yong Zhang; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2010-06-30       Impact factor: 15.419

3.  Novel interactions of fluorinated nucleotide derivatives targeting orotidine 5'-monophosphate decarboxylase.

Authors:  Melissa Lewis; Maria Elena Meza-Avina; Lianhu Wei; Ian E Crandall; Angelica Mara Bello; Ewa Poduch; Yan Liu; Christopher J Paige; Kevin C Kain; Emil F Pai; Lakshmi P Kotra
Journal:  J Med Chem       Date:  2011-03-21       Impact factor: 7.446

Review 4.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

5.  Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro.

Authors:  P K Rathod; A Khatri; T Hubbert; W K Milhous
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

6.  In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism.

Authors:  S A Queen; D L Jagt; P Reyes
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 7.  Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria.

Authors:  Rodrigo G Ducati; Hilda A Namanja-Magliano; Vern L Schramm
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

8.  Leaving group activation and pyrophosphate ionic state at the catalytic site of Plasmodium falciparum orotate phosphoribosyltransferase.

Authors:  Yong Zhang; Hua Deng; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2010-11-10       Impact factor: 15.419

9.  Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis.

Authors:  Carola Huthmacher; Andreas Hoppe; Sascha Bulik; Hermann-Georg Holzhütter
Journal:  BMC Syst Biol       Date:  2010-08-31

10.  Data mining of the transcriptome of Plasmodium falciparum: the pentose phosphate pathway and ancillary processes.

Authors:  Zbynek Bozdech; Hagai Ginsburg
Journal:  Malar J       Date:  2005-03-18       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.